Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06994507

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial of GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer（Gypsophila )

Sponsor: Qilu Pharmaceutical Co., Ltd.

Conditions Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions GM1 Placebo

Updated 2 times since 2025 Last updated: Aug 5, 2025 Started: Aug 1, 2025 Primary completion: Sep 30, 2026 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chemotherapy-induced Peripheral Neuropathy (CIPN), this trial is actively recruiting participants. The trial is conducted by Qilu Pharmaceutical Co., Ltd. and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qilu Pharmaceutical Co., Ltd.

Data source: Qilu Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China